Present and future drug treatment for Parkinson's disease

Staging of brain pathology related to sporadic Parkinson’s disease

2002 • 9,557 citations

Levodopa and the Progression of Parkinson's Disease

2004 • 1,703 citations

Molecular Pathways of Neurodegeneration in Parkinson's Disease

2003 • 1,634 citations

A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa

2000 • 1,513 citations

Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease

2003 • 1,275 citations

Neurodegeneration Prevented by Lentiviral Vector Delivery of GDNF in Primate Models of Parkinson's Disease

2000 • 1,255 citations

Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease

1993 • 1,208 citations

The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service

2002 • 1,178 citations

Rivastigmine for Dementia Associated with Parkinson's Disease

2004 • 1,153 citations

Sydney multicenter study of Parkinson's disease: Non‐<scp>L</scp>‐dopa–responsive problems dominate at 15 years

2004 • 1,013 citations

Effects of Coenzyme Q10 in Early Parkinson Disease

2002 • 965 citations

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study

2003 • 832 citations

Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial

2000 • 817 citations

Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD

2003 • 804 citations

Where Does Parkinson Disease Pathology Begin in the Brain?

2002 • 747 citations

Idiopathic hyposmia as a preclinical sign of Parkinson's disease

2004 • 716 citations

Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression

2002 • 686 citations

Pathology of Parkinson’s disease

1991 • 674 citations

Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease

1999 • 577 citations

Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease

2004 • 557 citations

A Controlled Trial of Rasagiline in Early Parkinson Disease

2002 • 555 citations

Excessive Daytime Sleepiness and Sudden-Onset Sleep in Parkinson Disease

2002 • 549 citations

A Controlled, Randomized, Delayed-Start Study of Rasagiline in Early Parkinson Disease

2004 • 488 citations

Oxidants and the central nervous system: some fundamental questions. Is oxidant damage relevant to Parkinson's disease, Alzheimer's disease, traumatic injury or stroke?

1989 • 471 citations

Levodopa motor complications in Parkinson's disease

2000 • 466 citations

The Nighttime Problems of Parkinsonʼs Disease

1988 • 438 citations

Adenosine A_2A Antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in Parkinsonian monkeys

1998 • 359 citations

Levodopa in the treatment of Parkinson's disease: Current controversies

2004 • 358 citations

Comparison of pramipexole, fluoxetine, and placebo in patients with major depression

2000 • 358 citations

The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins?

2003 • 348 citations

Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease

2004 • 326 citations

The effect of deprenyl and levodopa on the progression of Parkinson's disease

1995 • 324 citations

Health related quality of life in Parkinson's disease: a prospective longitudinal study

2000 • 322 citations

Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up

2004 • 302 citations

Pain in Parkinson's disease

1986 • 299 citations

Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease

2003 • 292 citations

Early development of levodopa‐induced dyskinesias and response fluctuations in young‐onset Parkinson's disease

1991 • 289 citations

Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys

2002 • 284 citations

Neuroprotection in Parkinson Disease

2004 • 281 citations

Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: A randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial

2002 • 255 citations

Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study

2003 • 252 citations

Combined Use of the Adenosine A2A Antagonist KW-6002 with l-DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity but Not Dyskinesia in MPTP-Treated Monkeys

2000 • 248 citations

Effect of peripheral catechol‐O‐methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients

1994 • 246 citations

Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension

2001 • 242 citations

Anticholinergics for symptomatic management of Parkinson´s disease

2002 • 242 citations

Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease.

1995 • 241 citations

Double‐blind, placebo‐controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism

2003 • 234 citations

Duration of amantadine benefit on dyskinesia of severe Parkinson's disease.

2004 • 233 citations

Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions

1998 • 223 citations

Actions of adenosine A 2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP

1999 • 215 citations

Effect of Nondopaminergic Drugs on L-DOPA-Induced Dyskinesias in MPTP-Treated Monkeys

1993 • 179 citations

Management of Parkinson's disease: An evidence-based review

2002 • 174 citations

A Strong Correlation Exists between the Distribution of Retinal Ganglion Cells and Nose Length in the Dog

2003 • 168 citations

Rasagiline Mesylate, a New Mao-B Inhibitor for the Treatment of Parkinson's Disease: A Double-Blind Study as Adjunctive Therapy to Levodopa

2000 • 168 citations

Sleep Disruption in Parkinson's Disease

1994 • 164 citations

Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients

2004 • 159 citations

Urodynamic and neurophysiological evaluation in Parkinson's disease and multiple system atrophy.

1997 • 159 citations

Problems with long-term levodopa therapy for Parkinson's disease.

1994 • 157 citations

Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline

2003 • 155 citations

Fipamezole (JP‐1730) is a potent α₂ adrenergic receptor antagonist that reduces levodopa‐induced dyskinesia in the MPTP‐lesioned primate model of Parkinson's disease

2003 • 155 citations

Continuous dopamine-receptor stimulation in advanced Parkinson's disease

2000 • 149 citations

Amantadine for dyskinesia in Parkinson's disease

2003 • 138 citations

Long‐term outcome of quetiapine use for psychosis among parkinsonian patients

2003 • 138 citations

Nonmotor fluctuations in patients with Parkinson's disease

1996 • 137 citations

The ?2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions ofL-dopa in the MPTP-lesioned primate model of Parkinson's disease

1999 • 134 citations

Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants

1995 • 134 citations

Amantadine in Parkinson's disease

2003 • 132 citations

Systemic administration of adenosine A2A receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study

2000 • 125 citations

An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic Bcl-2 in human dopaminergic SH-SY5Y cells

2002 • 124 citations

Levodopa and the progression of Parkinson’s disease

2005 • 119 citations

Adenosine A2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats

2000 • 117 citations

Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats

2001 • 110 citations

SCH 58261, an A_2A adenosine receptor antagonist, counteracts parkinsonian‐like muscle rigidity in rats

2001 • 109 citations

Catalepsy induced by a blockade of dopamine D₁ or D₂ receptors was reversed by a concomitant blockade of adenosine A_2A receptors in the caudate‐putamen of rats

2001 • 109 citations

Levodopa-induced dyskinesias are improved by fluoxetine

1995 • 107 citations

Pramipexole protects against apoptotic cell death by non‐dopaminergic mechanisms

2004 • 103 citations

The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells.

2002 • 102 citations

Longitudinal evaluation of economic and physical impact of Parkinson's disease

2001 • 89 citations

Noradrenoceptor antagonism with idazoxan improves l-dopa-induced dyskinesias in MPTP monkeys

2000 • 89 citations

Pain in Parkinsonʼs disease

1985 • 82 citations

Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias

1999 • 81 citations

QUALITY OF LIFE AND CARE IN PARKINSON'S DISEASE

1995 • 76 citations

Type 2 Diabetes in Childhood: The American Perspective

2003 • 76 citations

Efficacy and Safety of Fixed-Dose Oral Sildenafil in the Treatment of Sexual Dysfunction in Depressed Patients with Idiopathic Parkinson's Disease

2002 • 75 citations

Levodopa prolongs life expectancy and is non-toxic to substantia nigra

2001 • 73 citations

Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease

2004 • 71 citations

Disease modification in Parkinson's disease

2004 • 66 citations

Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson’s disease

2004 • 63 citations

PINK, PANK, or PARK? A clinicians' guide to familial parkinsonism

2004 • 61 citations

Risk of Serious Extrapyramidal Symptoms in Patients With Parkinson's Disease Receiving Antidepressant Drugs: A Pharmacoepidemiologic Study Comparing Serotonin Reuptake Inhibitors and Other Antidepressant Drugs

2003 • 60 citations

Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease

2003 • 52 citations

Reproductive health effects and teratogenicity of antiepileptic drugs

2004 • 49 citations

Excessive daytime sleepiness in Parkinson's disease

2004 • 47 citations

The Effects of Different Repeated Doses of Entacapone on the Pharmacokinetics of L-Dopa and on the Clinical Response to L-Dopa in Parkinson's Disease

2001 • 47 citations

The Neuroregulatory Properties of L-DOPA. A Review of the Evidence and Potential Role in the Treatment of Parkinson's Disease

1997 • 46 citations

Differential gene expression induced by chronic levodopa treatment in the striatum of rats with lesions of the nigrostriatal system

2004 • 45 citations

Adenosine Receptors and Parkinson's Disease

2000 • 38 citations

Dual dopamine agonist treatment in Parkinson’s disease

2003 • 34 citations

Effects of an alpha2 antagonist ina 20-year-old Java monkey with MPTP-induced parkinsonian signs

1991 • 29 citations

Absence of neurotoxicity of chronic L-DOPA in 6-hydroxydopaminelesioned rats

1997 • 28 citations

Neuroprotection in Parkinson Disease

2003 • 25 citations

Adenosine A _2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats

2003 • 21 citations

The influence of religious beliefs on general practitioners' attitudes towards termination of pregnancy—a pilot study

2004 • 20 citations

Direct brain infusion of glial cell line derived neurotrophic factor in Parkinson disease

2003 • 18 citations

Use of the dopamine agonist cabergoline in the treatment of movement disorders

2002 • 16 citations

Sex and idiopathic Parkinson's disease.

2001 • 14 citations

Monoamine oxidase inhibitors—is it time to up the TEMPO?

2003 • 10 citations

Pramipexole protects against apoptotic cell death by non‐dopaminergic mechanisms

2004 • 8 citations

Levodopa in the treatment of Parkinson's disease: Current controversies

2005 • 5 citations

Vestibular brainstem disorders: Clinical syndromes in roll plane and their model simulation

2002 • 5 citations

Nonmotor fluctuations in patients with Parkinson's disease

1997 • 4 citations

Physiology of Adenosine Receptors in the Striatum

2000 • 4 citations

Urodynamic and Neurophysiological Evaluation in Parkinson's Disease and Multiple System Atrophy

1999 • 3 citations